Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.67 +0.97 (+2.27%)

Streaming Delayed Price Updated: 9:57 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stocks That Hit 52-Week Lows On Wednesday ↗

July 14, 2021

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low....

Via Benzinga

Analyzing Exelixis's Unusual Options Activity ↗

July 12, 2021

Shares of Exelixis (NASDAQ:EXEL) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $17.64. Sentiment: BULLISH Option...

Via Benzinga

After Plummeting More Than 23%, Is Exelixis a Buy? ↗

July 09, 2021

The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.

Via The Motley Fool

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results? ↗

July 09, 2021

The biotech stock plunged after disappointing clinical results.

Via The Motley Fool

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

July 08, 2021

From Exelixis, Inc.

Via Business Wire

Fireworks Display ↗

July 05, 2021

The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.

Via Talk Markets

End Of June ↗

June 30, 2021

Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made.

Via Talk Markets

Topics Initial Public Offering

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

June’s Best and Worst Performing Russell 1,000 Stocks ↗

June 29, 2021

The month of June, the second quarter and the first half of 2021 are almost in the bag.

Via Talk Markets

Saint Warren ↗

June 28, 2021

Today the WTI oil price rose further up over 1%.

Via Talk Markets

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher ↗

June 28, 2021

Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has...

Via Benzinga

Topics Stocks

Exelixis Stock Collapses; Can It Recover From Mixed Results In Liver Cancer Study? ↗

June 28, 2021

Exelixis reported mixed results for its advanced liver cancer treatment on Monday and EXEL stock collapsed to a seven-month low.

Via Investor's Business Daily

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA

Via Benzinga

Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump ↗

June 28, 2021

Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the...

Via Benzinga

Topics Stocks

Here's Why Exelixis Stock Is Dropping Today ↗

June 28, 2021

The company reported successful clinical trial results, but investors were still disappointed.

Via The Motley Fool

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion....

Via Benzinga

The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus ↗

June 27, 2021

Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big...

Via Benzinga

Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence

June 18, 2021

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗

June 15, 2021

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...

Via Benzinga

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors

June 14, 2021

From Exelixis, Inc.

Via Business Wire

Unheeding Markets ↗

June 10, 2021

Today oil prices rose over $70.

Via Talk Markets

Here's What Crushed Exelixis' Earnings ↗

June 06, 2021

R&D spending is hurting earnings, but long-term investors shouldn't be worried.

Via The Motley Fool

Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma

June 04, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma

June 04, 2021

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Exelixis, Inc. - Common Stock (NQ:EXEL)

All News about Exelixis, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today